WO2001080868A1 - Nouveaux medicaments a base de melanges de sesquiterpenes - Google Patents
Nouveaux medicaments a base de melanges de sesquiterpenes Download PDFInfo
- Publication number
- WO2001080868A1 WO2001080868A1 PCT/FR2001/001327 FR0101327W WO0180868A1 WO 2001080868 A1 WO2001080868 A1 WO 2001080868A1 FR 0101327 W FR0101327 W FR 0101327W WO 0180868 A1 WO0180868 A1 WO 0180868A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- pharmaceutical compositions
- compositions according
- farnesol
- bisabolol
- geraniol
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/075—Ethers or acetals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Definitions
- the invention relates to new drugs based on mixtures of sesquiterpenes and / or sesquiterpene derivatives.
- Sesquiterpenes are formed from repetitions of C5 isoprenoid units and for many of them are active ingredients of natural essences.
- the inventors have now found a synergistic effect of certain mixtures of sesquiterpenes of great interest in oncology, or derivatives of sesquiterpenes, for specific therapeutic indications. These therapeutic indications are linked to the specific accumulation of these sesquiterpenes in rapidly renewing tissue masses, of physiological or pathological type, such as tumor masses.
- the invention therefore aims to provide new drugs to specific anti-tumor effect based on mixtures of sesquiterpenes and / or sesquiterpene derivatives.
- sesquiterpene as used in the description and the claims, will denote either sesquiterpenes alone or their derivatives.
- compositions for the preparation of medicaments for the prevention and / or the treatment of epithelial tissues or of connective tissues.
- compositions according to the invention are characterized in that they contain, where appropriate in combination with a pharmaceutically inert vehicle, a therapeutically effective amount of a mixture of ⁇ -bisabolol and farnesol and / or geraniol and / or their derivatives, in particular functional derivatives such as their esters, for example with methohexate, their ethers, in particular with hydroxylated compounds such as adriamycin, alkyl ethers of 1 to 4 carbon atoms, or glycosyl derivatives.
- a pharmaceutically inert vehicle a therapeutically effective amount of a mixture of ⁇ -bisabolol and farnesol and / or geraniol and / or their derivatives, in particular functional derivatives such as their esters, for example with methohexate, their ethers, in particular with hydroxylated compounds such as adriamycin, alkyl ethers of 1 to 4 carbon atoms, or glycosyl derivatives.
- Cx-bisabolol is a cyclic sesquiterpene of formula:
- Geraniol is also a linear sesquiterpene and corresponds to the formula:
- compositions according to the invention contain, in their active principle, from 99 to 1% of ⁇ -bisabolol and, respectively, from 1 to 99% of farnesol and / or geraniol, and in particular from 90 to 10% of ' ⁇ -bisabolol and, respectively, from 10 to 90' .. of farnesol and / or geraniol, where appropriate in the form of their derivatives, as defined above.
- the ⁇ -bisabolol is advantageously present in proportions at least equal to those of farnesol, or higher.
- the invention thus relates in particular to pharmaceutical compositions containing in their active principle 99 to 50% of ⁇ -bisabolol and, respectively 1 to 5 . 0% farnesol, and in particular 90 to 50% ⁇ -bisabolol and, respectively, 10 to 50% farnesol, as with geraniol.
- the geraniol In the compositions containing, in admixture with the ⁇ -bisabolol, farnesol and geraniol, the geraniol is generally in lower proportions, or at most equal to those of farnesol. These sesquiterpenes are thus for example in particular in ratios of 35.35.30% to 40.20.20% or 20.40.40% respectively in farnesol, geraniol and ⁇ -bisabolol.
- the pharmaceutical compositions defined above can also contain one or more other linear or cyclic sesquiterpenes.
- sesquiterpenes with a bisabolan nucleus such as the lanceol, or else with a guaiane nucleus, with the group of gua ⁇ anolides and derivatives with a patchoulane nucleus.
- These compounds can represent from 1 to 5% in the compositions defined above, it being understood that their proportion is always lower than that of farnesol, geraniol and ⁇ -bisabolol or their derivatives.
- the levorotatory forms are particularly preferred for therapeutic applications, the other forms being more especially used as laboratory reagents.
- sesquiterpenes of the mixtures according to the invention are widely used in perfumery and are therefore readily available as commercial products. As mentioned above, they can also be obtained by synthesis or by extraction from plants.
- one or more of their -OH groups can be advantageously blocked by a protective group by operating according to conventional techniques.
- one or more of these -OH groups can be functionalized to confer particular properties on the compounds, and in particular to allow their use as prodrugs. Examples that may be mentioned are esters, in particular acetates, or esters with methohexate and, as indicated above, ethers, in particular with hydroxylated compounds such as adriamycin, alkyl ethers of 1 to 4 carbon atoms. , or glycosyl derivatives.
- the LD 50 is thus 7.5 g / kg in the male mouse, greater than 9.75 g / kg in the male rat or the female rat, and 12 g / kg in the female mouse.
- the LD 5 o measured is greater than lg / kg (1.25 g / kg in the male mouse, 1.3 g / kg in the female mouse and 1.80 g / kg in the female rat, 1 , 90 g / kg in male rats).
- the pharmaceutical compositions contain, where appropriate, active principles from other drugs. Mention will be made in particular of their association with the water-soluble and liposoluble vitamins, amino acids such as D-alanine and with anti-tumor agents.
- antimitotic agents which can be used are alkylating agents, nitrosoureas, organoplastins, antifolics, antipurics, antipyriids, topoisomerase inhibitors, spindle agents, and hormonal and non-hormonal cytostatic agents.
- antibiotics such as penicillins, cephalosporins, beta-lactams, aminoglycosides, lincosamides, polymyxins, quinolones, nitroso-5-amidazoles, sulfonamides, teicoplanins, vincomycin (or any other antitumor agent active).
- compositions of the invention will also be used with advantage in combination with compounds facilitating their assimilation, such as sugars such as glucose, proteins for example hydrolysates of animal proteins, in particular fish, or lipids, such as oils.
- compounds facilitating their assimilation such as sugars such as glucose, proteins for example hydrolysates of animal proteins, in particular fish, or lipids, such as oils.
- food such as rapeseed, sunflower or olive. It is also advantageous to combine, depending on the location of the tumor, a surgical treatment and / or a chemotherapy or radiotherapy therapy with the treatment with administration of compositions according to the invention.
- compositions of the invention can be administered in different forms. They can thus be administered orally, dermally, or injectable, subcutaneously, venously, or intramuscularly, or even rectally.
- compositions advantageously contain from 7 to 25 g of active principle per intake unit, preferably from 5 to 10 g (corresponding to intakes ranging from 0.1 to 0.7 to 0.8 g / kg of body weight)
- the doses are between 2 and 15 g in one or more applications.
- solutions for injection by intravenous, subcutaneous or intramuscular route prepared from solutions, sterile or sterilizable, and distributed in different packages, for example 10, 50, 100, 500 and 1000 ml. It can also be suspensions or emulsions.
- injectable forms contain, per dosage unit, from 10 to 50 g of active principle, preferably from 10 to 25 g.
- suppositories are used as dosage forms.
- compositions according to the invention in normal rats has shown that the mixtures of sesquiterpenes of the active principles are fixed and accumulate in tissues with rapid cell renewal.
- compositions of the invention are therefore especially suitable for the treatment of any cancer: digestive, uterine, vaginal cancers, tumors of the pharynx and larynx, melanomas of the skin, pancreatic cancers, lymphoma, lungs, prostate, bladder, bone , etc.
- the dosage usable in humans, for the treatment of mammary or pulmonary tumors corresponds to the following doses: 7 to 25 g / day (0.1 to 0.7 g / kg) of active ingredient at base of mixtures of sesquiterpenes, in one or more doses.
- the invention relates to the use of mixtures of sesquiterpenes defined above for the development of anti-tumor drugs. Eue also targets their use as laboratory reagents serving as a reference in studies of anti-tumor activities of products to be tested.
- FIGS. 1 to 6 which represent the effect, on cells in culture, respectively:
- FIG. 4 of a mixture of farnesol and ⁇ -bisabolol at different concentrations, compared to farnesol alone
- FIG. 5 of a mixture of geraniol and ⁇ -bisabolol at different concentrations, compared to geraniol alone
- Example 1 Comparative study of the activity on the MCF7 line of farnesol (F) on the one hand and of a mixture according to the invention of farnesol and ⁇ -bisabolol (F + B) on the other hand
- the cells of the MCF7 line are rapidly growing breast adenocarcinoma cells.
- the doses tested during these tests are 0.1.10 ⁇ and 0, 5.10 " 'M.
- 1/100 dilutions are made extemporaneously in the RPMI alone and stirred so as to obtain a homogeneous emulsion at the time of use.
- the average number of cells seeded is approximately 10 million for each of the trials.
- PBS-EDTA recovered using 10 ml of RPMI 10% FCS, then counted using a Malassez cell.
- Second test search for an effect on MCF7 cells at a dose of 0.1 lMM.
- the procedure is as above, but by seeding with the _ _2 th transplanting of the cells and using doses of 0.1 mM
- the cells of cells in culture have a homogeneous adherent bed of cells with a few dead cells, the medium is orange in color.
- the box containing F 0.5 mM shows few adherent cells and a large number of floating cells (dead), the medium is of purple hue.
- the box containing a 0.5 mM F + B mixture shows agglomerated cells, floating (dead) in large numbers, the medium is of purple hue. There are only rare adherent cells.
- the box containing B 0.5 mM shows few adherent cells and a large number of floating cells (dead), the medium is of purple hue. This aspect is comparable to that of culture with F alone.
- Second test Test at a dose of 0.1 mM
- the dish of cells in culture has a homogeneous adherent bed of cells with a few dead cells, the medium is of orange tint.
- the boxes containing B have a homogeneous adherent bed of cells with a few dead cells, the medium is orange in color. This aspect is comparable to that of the control box.
- the box containing only 0.1 mM F shows few adherent cells and a large number of floating cells (dead), the medium is of purple hue.
- the box containing a 0.1 mM F + B mixture shows few adherent cells and a large number of floating cells (dead), the medium is of purple hue.
- test indicator 12780.10 3 - F only 0.1 mM: 385.10 3
- Example 2 Comparative study of the activity on 5mF RIN cells of farnesol (F) or geraniol (G) on the one hand and of mixtures according to the invention, respectively, of farnesol and of ⁇ -bisabolol (F + B) or geraniol and ⁇ -bisabolol (G + B)
- pancreatic tumor cells have been associated with non-tumor pancreatic cells
- the various compositions of farnesol, geraniol and ⁇ -bisabolol have selectively destroyed only the pancreatic cells tumor.
- the patient is administered the following products:
- Coupled treatment (over 1 week)
- Zophrène ® 1 or tablet of 4 to 8 mg / d combined with: - Holoxan: 0.5 and 3 g / irr
- Cis-platinum 10 to 120 mg / itr
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/258,667 US20040072915A1 (en) | 2000-04-27 | 2001-04-27 | Novel medicines based on sesquiterpene mixtures |
AU2001256445A AU2001256445A1 (en) | 2000-04-27 | 2001-04-27 | Novel medicines based on sesquiterpene mixtures |
CA002407442A CA2407442A1 (fr) | 2000-04-27 | 2001-04-27 | Nouveaux medicaments a base de melanges de sesquiterpenes |
EP01929759A EP1276489A1 (fr) | 2000-04-27 | 2001-04-27 | Nouveaux medicaments a base de melanges de sesquiterpenes |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR00/05403 | 2000-04-27 | ||
FR0005403A FR2808196A1 (fr) | 2000-04-27 | 2000-04-27 | Nouveaux medicaments a base de melanges de sesquiterpenes |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2001080868A1 true WO2001080868A1 (fr) | 2001-11-01 |
Family
ID=8849673
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/FR2001/001327 WO2001080868A1 (fr) | 2000-04-27 | 2001-04-27 | Nouveaux medicaments a base de melanges de sesquiterpenes |
Country Status (6)
Country | Link |
---|---|
US (1) | US20040072915A1 (fr) |
EP (1) | EP1276489A1 (fr) |
AU (1) | AU2001256445A1 (fr) |
CA (1) | CA2407442A1 (fr) |
FR (1) | FR2808196A1 (fr) |
WO (1) | WO2001080868A1 (fr) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004091594A1 (fr) * | 2003-04-15 | 2004-10-28 | Institut National De La Sante Et De La Recherche Medicale | Utilisation du geraniol dans une therapie anti-tumeur |
WO2005049001A1 (fr) | 2003-11-13 | 2005-06-02 | Compton Developments Ltd | Composes terpeniques antitumoraux |
WO2008029136A1 (fr) * | 2006-09-05 | 2008-03-13 | Ultra Biotech Limited | Composition pharmaceutique et méthode de traitement du cancer basée sur l'utilisation combinée d'agents anticancéreux dérivés de plantes ou classiques et d'huile de géranium ou de composés de cette dernière |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2342403A1 (fr) * | 2001-03-28 | 2002-09-28 | Jean Legault | Derives de sesquiterpene comme agents anticancereux |
CA3026108A1 (fr) | 2016-06-10 | 2017-12-14 | Clarity Cosmetics Inc. | Formulations non comedogenes de soin des cheveux et du cuir chevelu et methode d'utilisation |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2697133A1 (fr) * | 1992-10-28 | 1994-04-29 | Transbiotech | Composition biocide et/ou biostatique et ses applications. |
DE29610074U1 (de) * | 1996-06-07 | 1996-09-26 | Hakle Werke Hans Klenk Gmbh & | Trockenes Toilettenpapier |
US5602184A (en) * | 1993-03-03 | 1997-02-11 | The United States Of America As Represented By Department Of Health And Human Services | Monoterpenes, sesquiterpenes and diterpenes as cancer therapy |
WO1999045912A1 (fr) * | 1998-03-12 | 1999-09-16 | Wisconsin Alumni Research Foundation | Derives de monoterpenoide permettant de traiter le cancer |
WO1999066796A1 (fr) * | 1998-06-22 | 1999-12-29 | Wisconsin Alumni Research Foundation | Procede pour sensibiliser des cellules microbiennes vis-a-vis de composes antimicrobiens |
WO2000062744A2 (fr) * | 1999-04-19 | 2000-10-26 | The Procter & Gamble Company | Compositions de soin pour la peau contenant une combinaison de principes actifs de soin pour la peau |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5731303A (en) * | 1985-12-04 | 1998-03-24 | Conrex Pharmaceutical Corporation | Transdermal and trans-membrane delivery compositions |
US5747022A (en) * | 1993-07-30 | 1998-05-05 | Chesebrough-Pond's Usa Co., Division Of Conopco, Inc. | Cosmetic mask |
US5484597A (en) * | 1993-07-30 | 1996-01-16 | Chesebrough-Pond's Usa Co. | Clear hydroalcholic cosmetic microemulsions |
AT407821B (de) * | 1998-03-24 | 2001-06-25 | Franz Dr Stueckler | Mittel auf der basis von naturstoffen |
-
2000
- 2000-04-27 FR FR0005403A patent/FR2808196A1/fr not_active Withdrawn
-
2001
- 2001-04-27 US US10/258,667 patent/US20040072915A1/en not_active Abandoned
- 2001-04-27 EP EP01929759A patent/EP1276489A1/fr not_active Withdrawn
- 2001-04-27 AU AU2001256445A patent/AU2001256445A1/en not_active Abandoned
- 2001-04-27 CA CA002407442A patent/CA2407442A1/fr not_active Abandoned
- 2001-04-27 WO PCT/FR2001/001327 patent/WO2001080868A1/fr not_active Application Discontinuation
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2697133A1 (fr) * | 1992-10-28 | 1994-04-29 | Transbiotech | Composition biocide et/ou biostatique et ses applications. |
US5602184A (en) * | 1993-03-03 | 1997-02-11 | The United States Of America As Represented By Department Of Health And Human Services | Monoterpenes, sesquiterpenes and diterpenes as cancer therapy |
DE29610074U1 (de) * | 1996-06-07 | 1996-09-26 | Hakle Werke Hans Klenk Gmbh & | Trockenes Toilettenpapier |
WO1999045912A1 (fr) * | 1998-03-12 | 1999-09-16 | Wisconsin Alumni Research Foundation | Derives de monoterpenoide permettant de traiter le cancer |
WO1999066796A1 (fr) * | 1998-06-22 | 1999-12-29 | Wisconsin Alumni Research Foundation | Procede pour sensibiliser des cellules microbiennes vis-a-vis de composes antimicrobiens |
WO2000062744A2 (fr) * | 1999-04-19 | 2000-10-26 | The Procter & Gamble Company | Compositions de soin pour la peau contenant une combinaison de principes actifs de soin pour la peau |
Non-Patent Citations (4)
Title |
---|
BREHM-STECHER, B. F. (1) ET AL: "Sensitization of Staphylococcus aureus and Escherichia coli to antimicrobials by the sesquiterpenoid flavorant and aroma compounds nerolidol, farnesol, bisabolol and apritone.", ABSTRACTS OF THE GENERAL MEETING OF THE AMERICAN SOCIETY FOR MICROBIOLOGY, (2000) VOL. 100, PP. 535. PRINT. MEETING INFO.: 100TH GENERAL MEETING OF THE AMERICAN SOCIETY FOR MICROBIOLOGY LOS ANGELES, CALIFORNIA, USA MAY 21-25, 2000 AMERICAN SOCIETY FO, XP002940551 * |
BURKE ET AL: "Inhibition of pancreatic cancer growth by the dietary isoprenoids farnesol and geraniol", LIPIDS,US,CHAMPAIGN, IL, vol. 32, no. 2, February 1997 (1997-02-01), pages 151 - 156, XP002105998, ISSN: 0024-4201 * |
HE ET AL: "Isoprenoids suppress the growth of murine B16 melanomas in vitro and in vivo", JOURNAL OF NUTRITION,US,WISTAR INSTITUTE OF ANATOMY AND BIOLOGY, PHILADELPHIA, PA,, vol. 127, no. 5, May 1997 (1997-05-01), pages 668 - 674, XP002105994, ISSN: 0022-3166 * |
TORRADO ET AL: "Effect of dissolution profile and (-)-alpha-bisabolol on the gastrotoxicity of acetylsalicylic acid", PHARMAZIE,DD,VEB VERLAG VOLK UND GESUNDHEIT. BERLIN, vol. 50, no. 2, 1995, pages 141 - 143, XP002105999, ISSN: 0031-7144 * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004091594A1 (fr) * | 2003-04-15 | 2004-10-28 | Institut National De La Sante Et De La Recherche Medicale | Utilisation du geraniol dans une therapie anti-tumeur |
WO2005049001A1 (fr) | 2003-11-13 | 2005-06-02 | Compton Developments Ltd | Composes terpeniques antitumoraux |
WO2008029136A1 (fr) * | 2006-09-05 | 2008-03-13 | Ultra Biotech Limited | Composition pharmaceutique et méthode de traitement du cancer basée sur l'utilisation combinée d'agents anticancéreux dérivés de plantes ou classiques et d'huile de géranium ou de composés de cette dernière |
Also Published As
Publication number | Publication date |
---|---|
EP1276489A1 (fr) | 2003-01-22 |
FR2808196A1 (fr) | 2001-11-02 |
US20040072915A1 (en) | 2004-04-15 |
AU2001256445A1 (en) | 2001-11-07 |
CA2407442A1 (fr) | 2001-11-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Tanaka et al. | Chemoprevention of 4-nitroquinoline 1-oxide-induced oral carcinogenesis by dietary protocatechuic acid during initiation and postinitiation phases | |
EP1879656B1 (fr) | Composition pharmaceutique comprenant un antitumoral et un actif choisi notamment parmi le carveol , le thymol et le carvacrol | |
Mackenzie et al. | Phospho-sulindac (OXT-328), a novel sulindac derivative, is safe and effective in colon cancer prevention in mice | |
WO2005079827A2 (fr) | Agent anti-cancéreux | |
US20060024392A1 (en) | Compositions and methods for enhancing the effectiveness of a chemotherapeutic agent | |
JPH01501794A (ja) | カテコールブタン及び亜鉛を含む組成物 | |
EP0526608B1 (fr) | Agents therapeutiques pour le traitement de la resistance multidrogue de cancers | |
CA2435613C (fr) | Composition anti-atherosclerose contenant des carotenoides et procede d'inhibition de l'oxydation ldl | |
JP2023087054A (ja) | ミトコンドリア障害を処置するための方法 | |
WO2016060249A1 (fr) | Activateur de tie2 contenant un extrait de fruit d'olive | |
WO2001080868A1 (fr) | Nouveaux medicaments a base de melanges de sesquiterpenes | |
RU2492865C2 (ru) | Комбинированное применение производных холестанола | |
WO2007014379A2 (fr) | Extrait lipidique provenant de lepidium meynii et effet de celui-ci sur la libido | |
JP2015000056A (ja) | 菓子 | |
EP0232652A1 (fr) | Compositions nutritionnelles carencées en méthionine et supplémentées en homocystéine | |
JPWO2018164221A1 (ja) | 筋線維化抑制用組成物 | |
ES2905407T3 (es) | Composiciones que contienen curcumina con biodisponibilidad mejorada | |
WO2012147901A1 (fr) | Composition pour atténuer les effets secondaires d'un médicament anticancer | |
Wostmann et al. | The cholesterol-lowering effect of commercial diet fed to germfree and conventional rats | |
KR102224780B1 (ko) | 정향 추출물을 포함하는 대장암 표적치료제의 항암 활성 증진용 조성물 | |
FR2607006A1 (fr) | Composition pharmaceutique a base d'euphorbia pilulifera et/ou hirta, utilisee notamment comme cicatrisant et/ou desinfectant intestinal | |
KR102135148B1 (ko) | 악테오사이드를 함유하는 뇌종양 치료 및 전이 억제용 약학 조성물 | |
EP2440195B1 (fr) | Utilisation d'alkylglycerols pour la preparation de medicaments | |
JP4825957B2 (ja) | 抗腫瘍剤 | |
EP3427740B1 (fr) | Nouveau traitement du cancer par une combinaison d'un dérivé phosphorique d'inositol et de chlorure de magnésium |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2407442 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2001929759 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2001929759 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10258667 Country of ref document: US |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2001929759 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: JP |